FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087358022> ?p ?o ?g. }

• W2087358022 endingPage "888" @default.
• W2087358022 startingPage "874" @default.
• W2087358022 abstract "Objective: This study compared the efficacy and tolerability of a once-daily controlled-release formulation of hydromorphone (OROS® hydromorphone, Janssen-Cilag, Beerse, Belgium) and twice-daily extended-release (ER) oxycodone in patients with chronic, moderate to severe osteoarthritis (OA) pain. OROS hydromorphone is currently available only in Europe. Methods: Adults who met American College of Rheumatology clinical criteria for OA of the knee or hip with moderate to severe mean daily pain intensity despite chronic use of stable doses of NSAIDs or other nonsteroidal, nonopioid therapies were eligible for participation in this randomized, open-label study. The study consisted of a 14-day dose-titration and stabilization phase and a 28-day maintenance phase. OROS hydromorphone and ER oxycodone were initiated at dosages of 8 mg QD and 10 mg BID, respectively. Patients maintained diaries in which they rated their pain (from 0 = none to 3 = severe) and pain relief (from 0 = no relief to 4 = complete relief). Other assessments completed every 14 days included patient and investigator global evaluations of treatment effectiveness (scale from 1 = poor to 5 = excellent), the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, and the Medical Outcomes Study (MOS) Sleep Scale. Adverse events (whether observed by study personnel, identified in response to questioning, or spontaneously reported) and vital signs were monitored throughout the study. The primary efficacy measures were the mean pain relief score at end point and the time from initiation of treatment to the third day of moderate to complete pain relief, as reported in the patient diary. Noninferiority analyses were conducted on all primary and secondary efficacy variables. Results: One hundred thirty-eight patients (71 OROS hydromorphone, 67 ER oxycodone) received treatment (safety population), and 83 (60.1%) completed the study. Data from 124 patients were included in the efficacy analyses; the majority of these patients were white (85.5%) and female (69.4%), with a mean age of 63.6 years. The most commonly affected joint was the knee (79.8 %). At end point, the OROS hydromorphone group had a mean pain relief score of 2.3 (median, 2.0) and the ER oxycodone group had a mean pain relief score of 2.3 (median, 2.3) (95% CI, -0.30 to ∞). The mean time to the third day of moderate to complete pain relief was 6.2 days (median, 4.0) in the OROS hydromorphone group and 5.5 days (median, 5.0) in the ER oxycodone group (95% CI, -0.31 to ∞). Mean pain intensity decreased from baseline to end point by 0.6 point in the OROS hydromorphone group and by 0.4 point in the ER oxycodone group. Mean scores on the patient global evaluation improved by a respective 1.2 and 1.0 points (median, 1 in both groups). Approximately two thirds of patients in each group (67.2% and 66.7%) rated the overall effectiveness of treatment as good to excellent at end point. There were no statistically significant differences between groups in total WOMAC scores at end point, and similar improvements from baseline in the WOMAC physical function, stiffness, and pain scales were observed in both groups. Whereas MOS sleep outcomes scores improved from baseline in both groups, OROS hydromorphone was associated with a significantly greater improvement on the MOS Sleep Problems Index I compared with ER oxycodone (P < 0.045). Adverse events were comparable in both groups; the most frequently reported adverse events were nausea (35.2% and 29.9%), constipation (29.6% and 25.4%), somnolence (25.4% and 17.9%), vomiting (16.9% and 11.9%), and dizziness (14.1% and 22.4%). Adverse events led to study discontinuation in 35.2% (25/71) of patients in the OROS hydromorphone group and 32.8% (22/67) in the ER oxycodone group. Discontinuations due to adverse events during the titration phase were numerically greater in the OROS hydromorphone group (29.6% [21/71]) than in the ER oxycodone group (19.4% [13/67]). Only 1 serious adverse event (diarrhea in a patient receiving OROS hydromorphone) was considered possibly related to study drug. Conclusions: Once-daily OROS hydromorphone and twice-daily ER oxycodone provided similar pain relief in these patients with OA of the knee or hip. The tolerability profiles of the 2 agents were similar." @default.
• W2087358022 created "2016-06-24" @default.
• W2087358022 creator A5021286381 @default.
• W2087358022 creator A5025669021 @default.
• W2087358022 creator A5036744761 @default.
• W2087358022 creator A5048191133 @default.
• W2087358022 date "2007-05-01" @default.
• W2087358022 modified "2023-10-16" @default.
• W2087358022 title "Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis" @default.
• W2087358022 cites W1860477950 @default.
• W2087358022 cites W1984207232 @default.
• W2087358022 cites W2017586519 @default.
• W2087358022 cites W2023083223 @default.
• W2087358022 cites W2035833931 @default.
• W2087358022 cites W2036310725 @default.
• W2087358022 cites W2043033585 @default.
• W2087358022 cites W2043800177 @default.
• W2087358022 cites W2044329441 @default.
• W2087358022 cites W2048164399 @default.
• W2087358022 cites W2052533319 @default.
• W2087358022 cites W2058052863 @default.
• W2087358022 cites W2058147305 @default.
• W2087358022 cites W2058834020 @default.
• W2087358022 cites W2060855217 @default.
• W2087358022 cites W2070562467 @default.
• W2087358022 cites W2071858540 @default.
• W2087358022 cites W2096388167 @default.
• W2087358022 cites W2112870271 @default.
• W2087358022 cites W2115805053 @default.
• W2087358022 cites W2122160984 @default.
• W2087358022 cites W2123334658 @default.
• W2087358022 cites W2129860136 @default.
• W2087358022 cites W2133118804 @default.
• W2087358022 cites W2135119721 @default.
• W2087358022 cites W2136743000 @default.
• W2087358022 cites W2145322089 @default.
• W2087358022 cites W2157965141 @default.
• W2087358022 cites W2168514333 @default.
• W2087358022 cites W2177315914 @default.
• W2087358022 cites W2610860323 @default.
• W2087358022 cites W4238594081 @default.
• W2087358022 cites W4245703231 @default.
• W2087358022 cites W4248226706 @default.
• W2087358022 doi "https://doi.org/10.1016/j.clinthera.2007.05.016" @default.
• W2087358022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17697906" @default.
• W2087358022 hasPublicationYear "2007" @default.
• W2087358022 type Work @default.
• W2087358022 sameAs 2087358022 @default.
• W2087358022 citedByCount "75" @default.
• W2087358022 countsByYear W20873580222012 @default.
• W2087358022 countsByYear W20873580222013 @default.
• W2087358022 countsByYear W20873580222014 @default.
• W2087358022 countsByYear W20873580222015 @default.
• W2087358022 countsByYear W20873580222016 @default.
• W2087358022 countsByYear W20873580222017 @default.
• W2087358022 countsByYear W20873580222018 @default.
• W2087358022 countsByYear W20873580222019 @default.
• W2087358022 countsByYear W20873580222020 @default.
• W2087358022 countsByYear W20873580222021 @default.
• W2087358022 countsByYear W20873580222022 @default.
• W2087358022 crossrefType "journal-article" @default.
• W2087358022 hasAuthorship W2087358022A5021286381 @default.
• W2087358022 hasAuthorship W2087358022A5025669021 @default.
• W2087358022 hasAuthorship W2087358022A5036744761 @default.
• W2087358022 hasAuthorship W2087358022A5048191133 @default.
• W2087358022 hasConcept C126322002 @default.
• W2087358022 hasConcept C14184104 @default.
• W2087358022 hasConcept C142724271 @default.
• W2087358022 hasConcept C168563851 @default.
• W2087358022 hasConcept C170493617 @default.
• W2087358022 hasConcept C1862650 @default.
• W2087358022 hasConcept C197934379 @default.
• W2087358022 hasConcept C204787440 @default.
• W2087358022 hasConcept C2776029756 @default.
• W2087358022 hasConcept C2776164576 @default.
• W2087358022 hasConcept C2778375690 @default.
• W2087358022 hasConcept C2778715236 @default.
• W2087358022 hasConcept C2779158186 @default.
• W2087358022 hasConcept C2779286237 @default.
• W2087358022 hasConcept C2781063702 @default.
• W2087358022 hasConcept C2781118164 @default.
• W2087358022 hasConcept C42219234 @default.
• W2087358022 hasConcept C71924100 @default.
• W2087358022 hasConceptScore W2087358022C126322002 @default.
• W2087358022 hasConceptScore W2087358022C14184104 @default.
• W2087358022 hasConceptScore W2087358022C142724271 @default.
• W2087358022 hasConceptScore W2087358022C168563851 @default.
• W2087358022 hasConceptScore W2087358022C170493617 @default.
• W2087358022 hasConceptScore W2087358022C1862650 @default.
• W2087358022 hasConceptScore W2087358022C197934379 @default.
• W2087358022 hasConceptScore W2087358022C204787440 @default.
• W2087358022 hasConceptScore W2087358022C2776029756 @default.
• W2087358022 hasConceptScore W2087358022C2776164576 @default.
• W2087358022 hasConceptScore W2087358022C2778375690 @default.
• W2087358022 hasConceptScore W2087358022C2778715236 @default.
• W2087358022 hasConceptScore W2087358022C2779158186 @default.
• W2087358022 hasConceptScore W2087358022C2779286237 @default.
• W2087358022 hasConceptScore W2087358022C2781063702 @default.

• next